


# Conformity Assessment in Practice: Industry Challenges and Opportunities

Olga van Grol-Lawlor,  
Global Regulatory Intelligence & Advocacy, Associate Director,  
Boston Scientific.






# Introduction



**IMDRF:** Aim is to strategically **accelerate** international medical device regulatory **convergence** to promote an efficient and effective regulatory model for medical devices that is responsive to emerging challenges while protecting and maximizing public health.




IMDRF **Conformity Assessment** Guidance: Aim is to **harmonize** the documentation and procedures that are used to assess whether a medical device **conforms** to the regulations that apply in each jurisdiction. **Eliminating differences** between jurisdictions decreases the cost of gaining regulatory compliance and allows patients earlier **access** to new technologies and treatments.



What is the **industry experience** & how can we continue to **build** on the work done to date?

# Global Map of Regulated Markets




\*Source: Global Atlas of medical devices, WHO, 5 August 2017:  
<https://www.who.int/publications/i/item/9789241512312>

15 September 2025


## Industry Experience

- Complex global regulatory landscape.
- > 113 countries with a legal framework for medical devices\*.
- Navigating multiple regulatory frameworks.
- Increased resource demands on QA/RA teams.





## Key Challenges



## Case Study


### Drug Eluting Stent – Approval

**Benefits:** Optimal healing, ↑ deliverability, ↓ radiation exposure, ↓ procedure time, ↓ treatment cost.


**Launch market approval:** MC Country - 7 months

Market	Approval Timelines	Examples of Key Challenges	Status
Country Located in Europe (not EU)	2* yrs	Evolving framework, unique requirements, ↑ site audit...	Ongoing
Country located in Middle East	> 3* yrs	Pharma legislation – additional lab analysis...	Ongoing
Country Located in East Asia	~ 3* yrs	Type approval, local standards & clinical data, unique IFU...	Ongoing
Country Located in South Asia	5-6* yrs	Regulatory infrastructure not ready, capacity limitations at MOH...	Ongoing

\* Expected timeline based on previous experience



## Opportunities




15 September 2025

## Case Study

### Drug Eluting Stent – Approval contd.

Market	Traditional Pathway	Approval Time	Examples of Key Opportunities	Status
Country located in SE Asia	8-10 months	9 months	International best practice & standards	Approved
Country Located in Oceania	12-18 months	20 days	Reliance	Approved
Country Located in South America	6-15 months	2 months	Reliance	Approved
Country located in Europe (not EU)	NA	2 months	Reliance	Approved





## Impact & Recommendations



Poorly functioning conformity assessment pathways **impact patient access** to safe, high quality, effective and innovative medical devices.




Enhance global health equity by implementing **convergent conformity assessment pathways**, based on internationally recognized best practice & standards\*.



Implement regulatory **reliance**, including **recognition**\*.




## Conclusion



Conformity assessment is the key to patient safety, building trust & enabling global access.



Industry is committed to continued dialogue with IMDRF.



Shared vision – predictable, efficient and harmonized global regulatory frameworks.